Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 41

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 41
---
 the world pay close attention to the development of the biotechnology sector and provide support and funding. We intend to seek government support from the governments in the United States, the United Kingdom, Hong Kong, Singapore and elsewhere for our product development and to facilitate the development of some of our projects. |

Aptorum’s corporate strategy has been to license cutting edge medical technologies that we deem to have substantial potential value. DiamiR’s liquid biopsy for the mild cognitively impaired patients fits with the technologies that we are looking for as it provides minimally invasive and early diagnosis of a disease that will impact an ever-growing aging population. Arrangements with Other Parties Historically, we licensed early-stage programs from universities and further development work is mainly conducted in universities via SRAs. As for the development of our drug candidates, our R&D Center conducts part of the CMC work. However, since our current facilities are not cGMP, cGLP or cGCP qualified, we will have to rely on CROs to conduct that type of work, if and when our drug candidates reach the level of development that requires such qualification. Company’s Securities Our authorized share capital is divided into Class A Ordinary Shares and Class B Ordinary Shares. Holders of Class A Ordinary Shares and Class B Ordinary Shares have the same rights except for voting and conversion rights. In respect of matters requiring a shareholder vote, each Class A Ordinary Share will be entitled to one vote and each Class B Ordinary Share will be entitled to 100 votes. Due to the Class B Ordinary Share’s voting power, the holders of Class B Ordinary shares have a concentration of voting power, which limits the holders of Class A Ordinary Shares’ ability to influence corporate matters. (See “Risk Factors – Risks Related to our securities – Our Class B Ordinary Shares have greater voting power than our Class A Ordinary Shares and certain existing shareholders have substantial influence over our Company and their interests may not be aligned with the interests of our other shareholders.”)Each Class B Ordinary Share is convertible into one Class A Ordinary Share at any time by the holder thereof. Class A Ordinary Shares are not convertible into Class B Ordinary Shares under any circumstances. (See “Description of Share Capital”) Summary Risk Factors The following summarizes some, but not all, of the risks provided below. Please carefully consider all of the information discussed in “Risk Factors” in this registration statement for a more thorough description of these and other risks. Risks Related to the Merger

| ● | Risks related to not completing the Merger